For citations:
Paltuev R.M., Volynshchikova .A., Abdullaeva .R., Aleksakhina S.N., Artemyeva .S., Baychorov .A., Bakharev S.Yu., Belaya Yu.A., Bozhok .A., Vasin .A., Vladimirov V. ., Vorontsov A.Yu., Gaysina E. ., Gofman A.A., Dmitriev .N., Imyanitov .N., Klimenko .V., Komyakhov A.V., Konstantinova M.M., Kopp M.V., Kudaybergenova A.G., Lalak .A., Matevosyan D.L., Mudzhiri N.M., Poltareva O.V., Sevryukova .I., Semiglazov V.F., Semiglazova T.Yu., Urezkova M.M., Chichkanova A.S., Churilova L.A., Shomova M.V. Assessment of ERBB2 and HER2 expression in metastatic breast cancer using the nCounter® system and a 100-gene scale. Tumors of female reproductive system. 2023;19(3):30-36. (In Russ.) https://doi.org/10.17650/1994-4098-2023-19-3-30-36
Email this article 